Protocol Ledger

NCT05548556 · Phase II · COMPLETED

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Interventional Phase II clinical trial protocol NCT05548556 sponsored by Roche / Genentech in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-07 Enrollment: 51 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05548556
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05548556
Protocol FieldVerified Registry Value
NCT IdentifierNCT05548556
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment51 participants (ACTUAL)
Registered Start Date2023-02-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05548556
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyOpen Hospital Dossier ->
Royal Victoria InfirmaryNewcastle upon Tyne, United KingdomOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI